CTI Biopharma cashes in milestone triggered $10 million from Teva

CTI BioPharma has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for Trisenox (arsenic trioxide).

Trisenox was acquired from CTI BioPharma by Cephalon, Inc., which was subsequently acquired by Teva.

The milestone was paid upon the agreement that Trisenox entered into with Cephalon under which CTI BioPharma can get up to an additional $60 million in payments upon achievement by Teva of specified sales and development milestones related to Trisenox.

Symcel, the company that makes assay tool for real-time cell metabolism measurements, calScreener – is expanding to bring its patented technology to the clinical antimicrobial susceptibility testing (AST) markets. The company states it

Adventist Health—a faith-based, nonprofit integrated health system serving more than 75 communities in California, Oregon and Hawaii—has received a positive outlook review from Fitch Ratings, Inc., one of the world’s leading financial ratings agencies.